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group, mail-order pharmacy users demonstrated a significantly higher PDC (0.68
vs. 0.61; P0.001) throughout the benefit year. More patients in the mail-order
pharmacy group (49.7%) were adherent with their oral antidiabetic medications
compared to 42.8% in the retail pharmacy group. CONCLUSIONS: Adherence with
oral anti-diabetic medications among Medicare Part D beneficiaries is suboptimal.
Patients using mail-order pharmacy were likely to have better adherence than
those who used retail pharmacies for their medication refills. The causal relation-
ship betweenmail-order pharmacy use and adherence, however, should be further
examined in a randomized study setting.
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OBJECTIVES: Non-adherence to insulin therapy in patients with type 2 diabetes
presents a serious challenge. Potential explanations for non adherence may in-
clude aversion to insulin self-injection and fear of hypoglycemic events. In clinical
trails, insulin analogs have shown to reduce the risk of hypoglycemic events versus
human insulins, and a recent review suggests that insulin delivered via a pen
device may result in greater adherence versus vial and syringe. This study was
conducted to compare the adherence rates of patients initiating basal insulin ther-
apy with insulin detemir (IDet) FlexPen® versus those initiating basal insulin ther-
apy with NPH via vial and syringe.METHODS: Data were gathered from a large US
national payer retrospective claims database, and included only patients with type
2 diabetes that initiated basal insulin therapy with either IDet FlexPen® or NPH in
vials. Patientswith claims for any other type of insulin, other than the index insulin
formulations during the 12-month observation period were excluded. Patients
were defined as being adherent to therapy if they had a medication possession
ration (MPR) of at least 0.80 in the 12-month follow up period. RESULTS: The IDet
FlexPen® cohort (n1082) and the NPH vial cohort (n794) were of similar age
(54.06 vs. 53.13, p0.134); however, the IDet FlexPen® cohort had a lower propor-
tion of female patients (44% vs. 55%, p0.001) and fewer patients without a history
of pre-index OADs (9% vs 45%, p0.001), than the NPH vial cohort. After controlling
for important confounders, patients initiating insulin therapy with IDet FlexPen®
were 39%more likely to achieve anMPR of 0.80 or greater versus patients initiating
insulin therapy with NPH vial (95% CI: 1.04-1.85). CONCLUSIONS: These results
suggest that adherence may be improved for patients initiating basal insulin ther-
apy with IDet in the FlexPen® versus NPH in a vial.
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OBJECTIVES: To describe adherence with growth hormone (GH) treatment by age
group among newly initiated patients. METHODS: Somatropin pharmacy claims
were selected from July 1999 throughMay 2008 in PharMetrics, a nationalmanaged
care dataset. Continuous eligibility for 6 months before and 12 months after the
first GH prescription (i.e., index date) was required. Patients were excluded if they
had: claims for brands of somatropin used for HIV-associated wasting; potential
data entry errors in key variables; or had a claim for GH product no longer on the
market. Adherence was assessed using medication possession ratios (MPRs) de-
fined as the sum of days supply divided by 360 days of observation and capped at
100%. Evaluations by age group included average MPR, percentage of patients with
at least 80%MPR, and percentage of patients who stay on therapy (i.e., persistence)
for at least 80% of the observation period. RESULTS: A total of 1355 patients receiv-
ing GH met study criteria; 64.0% males and 36.0% females. The percentage of pa-
tients receiving GH by age category was as follows:4 (5.2%), 4 to13 (40.9%), 13 to
18 (34.8%), 18 (19.1%). Average MPR was greatest in the 4 age group (87.2; SE
2.8), followed by 4 to13 (82.9; SE 1.0), 13 to18 (80.5; SE 1.1) and 18 (68.1; SE 1.5).
Patients in the 18 groups had significantly lower mean MPR (68.1% SD 27.2) than
all other age groups (all above 80%; p0.0001). The percentage of patients with an
MPR of at least 80%was 71.4%, 69.3%, 66.1% and 44.8%, respectively. Approximately
89% of the 4 to 13 age group remained on therapy (i.e., persisted) for more than
80% of the observation period versus only 64.5% of the 18 group. CONCLUSIONS:
Adherence with growth hormone decreases as age increases. There is opportunity,
however, for improvement in all age groups.
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OBJECTIVES: To examine adherence to medications used in managing painful di-
abetic peripheral neuropathy (PDPN) and determine their association with oral
antidiabetic medication (OAD) adherence.METHODS: A retrospective cohort anal-
ysis using the Texas Medicaid prescription claims database. Study participants
were adult (30-64 years) Medicaid beneficiaries prescribed OAD and PDPNmedica-
tions. Data were extracted from June 1, 2003 to October 31, 2009. The study’s re-
search objectiveswere to: 1) provide a description of PDPNandOADmedication use
among the study subjects; 2) determine if PDPN medication adherence differs
among individual PDPN medication (i.e., TCAs, gabapentin, pregabalin and dulox-
etine); and 3) determine if PDPNmedication adherence is related to post-indexOAD
medication adherence while controlling for covariates. Adherence was measured
usingmedication possession ratio (MPR). RESULTS:A total of 4277 patientsmet the
study’s inclusion criteria. The overall mean MPR (SD) for PDPN medications was
75.4% (23.9%). Mean MPR differed significantly among individual PDPN medica-
tions (p0.0001). Mean MPR was highest for duloxetine (85.6%18.2%) and was
lowest for pregabalin (69.4%24.9%). The overall mean MPR (SD) for OAD medi-
cations decreased significantly (p0.0001) from 73.0% (24.3%) in the pre-index
period to 64.5% (25.6%) in the post-index period. After controlling for covariates,
non-adherers (i.e., MPR80%) to PDPN medications, compared to adherers (i.e.,
MPR80%), were significantly less likely to be adherent to OADmedications [Odds
Ratio (OR) 0.626; 95% CI0.545-0.719]. CONCLUSIONS: Patients’ adherence to
PDPN medications was associated with adherence to OAD medications. Patients
whowere adherent to PDPNmedicationsweremore adherent to OADmedications.
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OBJECTIVES: To determine treatment gap trends among first time GH recipients
using a large, USmanaged care database. To our knowledge, this is the first analysis
of gaps in GH treatment using a large sample of prescription claims. METHODS:
Somatropin pharmacy claims were selected from July 1999 through May 2008 in
PharMetrics, a national managed care dataset. Continuous eligibility for 6 months
before and 12 months after the first GH prescription (i.e., index date) was required.
Patients were excluded if they had: claims for brands of somatropin approved for
human immunodeficiency virus-associated wasting and short bowel syndrome in
patients receiving specialized nutritional support, potential data entry errors in
days supply, quantity dispensed or allowed amounts, had a claim for GH product
no longer on themarket, or incorrect doses based on data entry errors. The number
and percentage of patients with treatment gaps of at least 60 days were based on
reported days supply dispensing dates. RESULTS: A total of 1355 patients receiving
GH met study criteria. The study population consisted of 64.0% males and 36.0%
females. The percentage of patients receiving GH by age category were as follows:
4 (5.2%), 4 to13 (40.9%), 13 to18 (34.8%), 18 (19.1%). Gaps in therapy of 60 days
were calculated and results showed that 27.0% of GH patients discontinued their
medication for at least 60 days within 1 year of follow-up. CONCLUSIONS: Gaps in
therapy occur among approximately 27% of GH users during a one-year time pe-
riod, regardless of age or gender. Reasons for this therapeutic gap remain un-
known.
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BACKGROUND: Evidence regarding the value and utility of SMBG in insulin-naïve
type 2 diabetes (T2DM) has beenmixed. Failure to personally understand the value
associated with SMBG results and/or share SMBG data with healthcare providers
(HCPs) may contribute to poor treatment adherence. The Structured Testing Pro-
gram (STeP) study, a prospective, cluster-randomized,multi-centered clinical trial,
demonstrated that structured SMBG significantly improves glycemic control and
quality of life in non-insulin-treated T2DM. In the study, 483 poorly-controlled
(HbA1c 7.5%), insulin-naïve T2DM patients were randomized to structured test-
ing (STG) or active control (ACG). All STG and ACG patients received free blood
glucose meters and test strips. STG subjects also used the ACCU-CHEK® 360 View
Blood Glucose Analysis System (”tool”) quarterly to collect/interpret 7-point glu-
cose profiles over 3 consecutive days. STG patients then brought the tool to their
HCPs. OBJECTIVES: To evaluate STeP study patient perceptions regarding diabetes
self-management and interactionswithHCPs.METHODS:Aqualitative descriptive
design; data were collected via phone interviews with 59 (20 ACG, 39 STG) STeP
study participants. Data were analyzed using a content analysis approach.
RESULTS: Sample characteristics included: 54% male; 56% White; mean age 57.1
years; 49% some college or more; mean duration of T2DM 7.4 years; and mean
baseline HbA1c 8.9%. Although participants from both study arms perceived SMBG
as having personal value, STG patients reported additional benefits of using the
tool, including: more in-depth understanding of diabetes; increased confidence in
daily decision-making; more meaningful discussions with HCPs; and shared deci-
sion-making regarding treatment. CONCLUSIONS:Our findings suggest that use of
structured testing, as part of a comprehensive intervention where patients and
HCPs collaborate to gather, interpret and utilize SMBG data, promotes a positive
change in how patients view SMBG, improves patient comprehension of diabetes
and diabetes self-management, and increases patient participation in their treat-
ment regimens.
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